Raising Full Year Revenue, Gross Margin and Operating Margin Guidance
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024.
Second Quarter Financial Highlights:
Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in constant currency due to revenue outperformance for all product lines
Total Omnipod revenue of $480.4 million, an increase of 26.3%, or 26.5% in constant curr